周日直播｜2024年十月生物医药大事讨论

文章预览

本月热点 TOPICS 1 .    Oncology & Autoimmune Diseases： Revolution Medi cines presents initial data from RMC-9805 monotherapy in patients with advanced pancreatic ductal adenocarcinoma ； Novocure receives F DA approval for their electric field therapy in metastatic lung cancer; Zai Lab's DLL3-targeted ADC (ZL-1310) demonstrates promising ORRs and safety in extensive-stage SCLC; Vera announces Atacicept phase 2b study data of IgA nephropathy at ASN and follow-on raise of $300M;  Otsuka’s anti-APRIL sibeprenlimab shows promise in Phase 3 IgA nephropathy trial ； Amgen presents positive phase 3 data for Uplizna in myasthenia gravis at AANEM Annual Meeting; GSK acquires CD19/CD20/CD3 antibody from Chimagen Biosciences with $300M upfront； 2 .   New Modalities: Intellia’s in vivo CRISPR-based therapy reduces swelling attacks by 81% in phase 2 trial for hereditary angioedema; Results from Pfizer’s AAV gene therapy for Duchenne muscular dystrophy raise questions on micro ………………………………